Semax

Semax and Memory: Cognitive Performance Research

13 min read|March 25, 2026

Semax

1.4x BDNF

A single intranasal dose of Semax produced a 1.4-fold increase in BDNF protein and a 3-fold increase in BDNF mRNA in the rat hippocampus, the brain region most critical for memory formation.

Dolotov et al., Brain Research, 2006

View as image

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of the ACTH(4-10) fragment that crosses the blood-brain barrier through intranasal delivery and produces measurable changes in memory-related brain systems within minutes. A single dose increases brain-derived neurotrophic factor (BDNF) protein levels 1.4-fold in the rat hippocampus, activates both dopaminergic and serotonergic pathways, and alters the default mode network in human fMRI studies.^[1] The cognitive research on Semax is more mechanistically detailed than most nootropic peptides. It is also almost entirely Russian. For the full picture of Semax biology, see our overview of how Semax upregulates BDNF.

Key Takeaways

A single Semax dose (50 mcg/kg intranasal) produced a 1.4-fold increase in BDNF protein, 1.6-fold increase in TrkB phosphorylation, and 3-fold increase in BDNF mRNA in the rat hippocampus (Dolotov et al., 2006)
Semax activated dopaminergic and serotonergic systems in rat brain within 30 minutes of injection, with peak effects at 60 minutes (Eremin et al., 2005)
In 24 healthy human volunteers, intranasal Semax altered the default mode network on fMRI at 5 and 20 minutes post-administration (Lebedeva et al., 2018)
Semax decreased cortical infarction volume and prevented amnesia in a rat model of prefrontal ischemia (Romanova et al., 2006)
In a 2025 Alzheimer's disease mouse model, Semax reduced amyloid plaque count 2.8-fold compared to untreated controls (Radchenko et al., 2025)
Semax increased NGF and BDNF gene expression across hippocampus, frontal cortex, and retina with distinct temporal dynamics for each region (Shadrina et al., 2010)

The BDNF mechanism: why it matters for memory

Brain-derived neurotrophic factor is the single most important protein for long-term memory formation. It drives synaptic plasticity in the hippocampus, supports long-term potentiation (the cellular basis of memory encoding), and maintains the survival of neurons in memory circuits. When BDNF levels drop, memory declines. This is not theoretical; BDNF reduction is a documented feature of Alzheimer's disease, depression-related cognitive dysfunction, and age-related memory loss.

Dolotov and colleagues (2006) demonstrated that a single intranasal Semax application at 50 mcg/kg produced a cascade of BDNF-related changes in the rat hippocampus:^[1]

1.4-fold increase in BDNF protein levels
1.6-fold increase in TrkB tyrosine phosphorylation (the activated form of the BDNF receptor)
3-fold increase in exon III BDNF mRNA
2-fold increase in TrkB mRNA

The TrkB phosphorylation finding is particularly significant. BDNF protein levels can rise without functional consequences if the receptor is not activated. The fact that Semax simultaneously increased both the ligand (BDNF) and the activated receptor (phospho-TrkB) means the full signaling cascade was engaged.

In a companion paper, the same group showed that Semax binds specifically to basal forebrain tissue and increases BDNF levels there as well.^[2] The basal forebrain contains the cholinergic neurons that project to the cortex and hippocampus. These are the neurons that degenerate earliest in Alzheimer's disease. Semax's ability to reach them and stimulate BDNF production is the mechanistic basis for its cognitive claims.

Regional and temporal dynamics of neurotrophic gene expression

Memory does not live in one brain region. It requires coordinated activity across the hippocampus (encoding), prefrontal cortex (working memory, strategic retrieval), and supporting structures. Shadrina and colleagues (2010) mapped how Semax affects neurotrophic factor gene expression across multiple brain regions over time.^[3]

After intranasal Semax administration in rats, they measured NGF and BDNF mRNA levels at multiple time points in the hippocampus, frontal cortex, and retina. Each region showed a distinct temporal profile. The hippocampus responded fastest and most robustly for BDNF. The frontal cortex showed delayed but sustained NGF elevation. The retina had its own independent pattern.

This regional specificity matters because it shows Semax is not simply flooding the brain with neurotrophic factors. Different memory systems are being modulated on different timescales, which is consistent with how memory actually works: rapid hippocampal encoding followed by slower cortical consolidation.

Dopamine and serotonin: the dual monoamine activation

Memory formation requires more than neurotrophic support. It requires attention (dopamine) and emotional salience tagging (serotonin). Semax activates both systems.

Eremin and colleagues (2005) showed that Semax administration to rats activated dopaminergic and serotonergic brain systems with measurable changes in metabolite ratios appearing within 30 minutes.^[4] The dopaminergic effects were concentrated in the striatum and nucleus accumbens. The serotonergic effects appeared in the hippocampus and frontal cortex.

This dual activation explains why Semax's cognitive effects extend beyond pure memory. Dopamine-mediated attention improvements mean better encoding. Serotonin-mediated mood effects mean better consolidation (emotional memories are encoded more strongly than neutral ones). The combination is why Semax has been explored for attention-deficit conditions.

Tsai (2007) specifically proposed Semax as a candidate for attention-deficit hyperactivity disorder (ADHD) treatment based on its dopaminergic activation profile, arguing that its mechanism differs sufficiently from psychostimulants to warrant investigation in non-responders.^[5] This remains a hypothesis paper; no ADHD clinical trials have been conducted.

For comparison, Selank, developed by the same institute, was designed for anxiety rather than cognition but was studied alongside Semax in a functional connectivity study (Panikratova et al., 2020) that showed distinct patterns of brain network modulation for each peptide.^[6]

Human brain imaging: the default mode network study

Most Semax cognitive research is preclinical. The Lebedeva et al. (2018) fMRI study is one of the few to directly measure Semax's effects on brain activity in humans.^[7]

Twenty-four healthy volunteers (11 men, 13 women, mean age 43.9 years) received either intranasal 1% Semax or placebo. Resting-state fMRI was performed before, 5 minutes after, and 20 minutes after administration. The researchers measured the default mode network (DMN), a set of brain regions that are active during rest and involved in self-referential thinking, episodic memory retrieval, and mental simulation.

Semax produced measurable changes in DMN topology at both time points. A greater volume of DMN activation was observed in the Semax group. The DMN is directly involved in memory consolidation during rest periods. Its altered activity under Semax suggests the peptide may enhance the brain's ability to process and store information during the periods between active learning.

This study has limitations. The sample size is small (14 Semax, 10 placebo). The fMRI measured network activity, not cognitive performance directly. And the study only captured acute effects (20 minutes). Whether these DMN changes translate to measurably improved memory in humans requires larger, longer studies with cognitive testing as the primary outcome.

Neuroprotection and memory preservation in ischemia

Some of the strongest evidence for Semax's cognitive effects comes from models where memory is actively being destroyed. Romanova and colleagues (2006) tested Semax in a rat model of prefrontal cortex ischemia (simulated stroke).^[8]

Intranasal Semax administered for 6 days after photoinduced ischemia produced two results: it decreased the volume of cortical infarction (less brain tissue died), and it prevented the formation of amnesia as measured by passive avoidance conditioning. The animals retained learned behaviors that untreated ischemic animals lost.

Sudarkina et al. (2021) examined the protein expression changes underlying this neuroprotection. In a rat cerebral ischemia model, Semax treatment altered the expression of proteins involved in inflammation, apoptosis, and synaptic function, confirming that the behavioral protection has a molecular basis.^[9]

This neuroprotective memory preservation is why Semax is approved in Russia for stroke treatment. The cognition-relevant application there is not enhancement of normal memory, but prevention of memory loss after brain injury. These are fundamentally different clinical scenarios, and the evidence for the neuroprotective application is substantially stronger than for nootropic use in healthy individuals.

The Alzheimer's disease frontier

The most recent preclinical data comes from Radchenko et al. (2025), who tested both Semax and a derivative peptide in an Alzheimer's disease mouse model.^[10]

The mean number of amyloid plaques decreased 2.8-fold in the Semax group compared to untreated animals. Cognitive function assessments (open field, novel object recognition, Barnes maze) showed that both Semax and its derivative improved performance on tests of spatial memory and recognition memory.

These results are preclinical and should be interpreted with the knowledge that dozens of Alzheimer's interventions have succeeded in mice and failed in humans. But Semax's multi-target mechanism (BDNF elevation, anti-inflammatory action, anti-amyloid effects, dopaminergic activation) addresses multiple pathological features of Alzheimer's simultaneously, which is theoretically more promising than single-target approaches.

Mood, stress, and cognitive performance

Depression impairs memory. Chronic stress impairs memory. If Semax improves mood and stress resilience, that indirectly supports cognitive function.

Inozemtseva and colleagues (2024) demonstrated antidepressant-like and antistress effects of Semax in a chronic unpredictable stress model in male rats.^[11] Semax normalized stress-induced behavioral and neurochemical changes including those in the serotonergic system.

Glazova et al. (2021) showed that Semax attenuated behavioral and neurochemical alterations caused by early-life SSRI exposure in rats.^[12] This is relevant because perinatal SSRI exposure can produce lasting cognitive and emotional changes, and Semax's ability to normalize these suggests it can correct neurodevelopmental disruptions that affect adult cognition.

For readers interested in other peptides that bridge mood and cognition, see our overview of nootropic peptides.

What the evidence does not show

No large-scale human cognitive trials exist. The only published human data on Semax and cognition consists of the fMRI default mode network study (24 subjects, acute effects only), early Russian studies from the 1990s in small volunteer samples, and clinical use for stroke recovery. No Western-standard randomized controlled trial has tested Semax for memory enhancement in healthy people.

Healthy vs. impaired cognition. The strongest evidence is in damage models: ischemia, Alzheimer's mice, stress-induced cognitive decline. Whether Semax enhances memory in people with normal brain function is essentially untested in rigorous designs. Russian regulatory approval covers pathological conditions, not cognitive enhancement.

Dose and duration are poorly characterized. Most preclinical studies use a single dose or short courses. The long-term cognitive effects of repeated Semax administration, including tolerance, dependence, and safety, have not been systematically studied.

Almost all research comes from Russian institutions. The Institute of Molecular Genetics and collaborating Russian labs have produced the vast majority of Semax publications. Independent replication in Western labs is minimal. This concentration of research in one academic network introduces the possibility of shared methodological assumptions and biases that external replication would help identify.

BDNF elevation is not unique to Semax. Exercise, sleep, social interaction, and several other interventions also increase hippocampal BDNF. Whether Semax's BDNF-mediated effects on cognition exceed what can be achieved through behavioral interventions has never been compared head-to-head.

The Bottom Line

Semax produces a well-documented cascade of molecular changes relevant to memory: BDNF elevation in the hippocampus, TrkB receptor activation, dopaminergic and serotonergic system engagement, and altered default mode network activity in human brain imaging. The strongest cognitive evidence comes from neuroprotection models (stroke, Alzheimer's mice) rather than enhancement of normal memory. No large randomized controlled trial has tested Semax for cognitive enhancement in healthy humans. All evidence comes predominantly from Russian research groups, and independent replication is limited.

Frequently Asked Questions

In animal models, Semax increases BDNF protein 1.4-fold in the hippocampus (the primary memory center), prevents amnesia in stroke models, and improves spatial memory in Alzheimer's disease mice (Dolotov et al., 2006; Romanova et al., 2006; Radchenko et al., 2025). In humans, Semax altered default mode network activity on fMRI, a brain network involved in memory consolidation. However, no large randomized trial has measured memory improvement in healthy humans.

Semax crosses the blood-brain barrier through intranasal delivery and produces multiple measurable effects: a 1.4-fold increase in BDNF protein, activation of dopaminergic and serotonergic systems, and altered default mode network activity visible on fMRI within 5 minutes. It also increases TrkB receptor phosphorylation 1.6-fold, meaning the full neurotrophic signaling cascade is engaged (Dolotov et al., 2006; Eremin et al., 2005).

Semax has documented nootropic-relevant mechanisms: BDNF upregulation, dopamine system activation, and neuroprotective effects that preserve memory in brain injury models. It is classified as a nootropic drug in Russia and approved for conditions including stroke recovery and cognitive disorders. However, its effectiveness for cognitive enhancement in healthy individuals has not been tested in large Western-standard clinical trials.

Semax (ACTH 4-10 analog) is primarily nootropic and neuroprotective, targeting BDNF and dopamine/serotonin systems to enhance cognition. Selank (tuftsin analog) is primarily anxiolytic, targeting GABA receptors to reduce anxiety. An fMRI study in healthy volunteers showed distinct patterns of brain network modulation for each peptide (Panikratova et al., 2020). Both were developed at the same Russian institute and both have secondary effects in the other's primary domain.

Yes. A single intranasal dose of Semax (50 mcg/kg) produced a 1.4-fold increase in BDNF protein levels, a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in TrkB receptor mRNA in the rat hippocampus (Dolotov et al., 2006). A separate study showed Semax increased both NGF and BDNF gene expression across hippocampus, frontal cortex, and retina with region-specific temporal dynamics (Shadrina et al., 2010).

In a 2025 Alzheimer's disease mouse model, Semax reduced amyloid plaque count 2.8-fold and improved performance on spatial memory and recognition memory tests (Radchenko et al., 2025). Its multi-target mechanism (BDNF elevation, anti-inflammatory, anti-amyloid, dopaminergic) addresses multiple Alzheimer's pathologies simultaneously. However, these are preclinical results only. No human Alzheimer's clinical trial has been conducted with Semax.